LKT Labs

Biochemicals for Life Science Research

Saracatinib

Saracatinib

Product ID S0168
Cas No. 379231-04-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $45.00 In stock
5 mg $68.00 In stock
25 mg $225.00 In stock
Bulk Quote

Quicklinks

Description

Saracatinib is an inhibitor of Src and Abl family kinases that is used for its anticancer chemotherapeutic and immunomodulatory benefits. Saracatinib is currently in clinical trials as a potential treatment for a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, and myeloma. In cellular and animal models, this compound inhibits migration, invasion, and growth of cancer cells. Additionally, saracatinib displays mixed immunomodulatory effects, decreasing T cell cytokine production in one in vitro model and increasing CD8+ memory T cells and production of IFN-γ in another in vitro model.

Product Info

Cas No.

379231-04-6
Purity

≥98%
Formula

C27H32ClN5O5
Formula Wt.

542.03
Chemical Name

N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
IUPAC Name

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine
Synonym

AZD-0530
Appearance

Off white powder

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

S0168 MSDS PDF
Info Sheet

S0168 Info Sheet PDF

References

Gangadhar TC, Clark JI, Karrison T, et al. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun;31(3):769-73. PMID: 23151808.

Nam HJ, Im SA, Oh DY, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013 Jan;12(1):16-26. PMID: 23144237.

Cavalloni G, Peraldo-Neia C, Sarotto I, et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012 Jul;11(7):1528-38. PMID: 22452946.

Takai S, Sabzevari H, Farsaci B, et al. Distinct effects of saracatinib on memory CD8+ T cell differentiation. J Immunol. 2012 May 1;188(9):4323-33. PMID: 22450814.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • S1845

    L-(+)-Selenomethionine

    Naturally occurring amino acid found in grains,...

    ≥98%
  • R327201

    Rifapentine

    Antibiotic

    ≥97%
  • E5214

    α-Endorphin

    Endogenous opioid peptide; μOR agonist.

    ≥95%
  • R0110

    Ractopamine Hydrochloride

    β1/2-adrenergic agonist.

    ≥97%
  • S7601

    Statil

    Aldose reductase inhibitor.

    ≥98%
  • M0040

    M40

    Peptide; galanin antagonist.

    ≥95%
  • F130280

    FHD-286

    BRG1/BRM ATPase inhibitor

    ≥98%
  • B4974

    BMS-777607

    MET and Ron inhibitor.

    ≥99%
  • B0396

    BAY80-6946

    p110α PI3K inhibitor.

    ≥98%
  • A7618

    Atenolol

    β1-adrenergic antagonist.

    ≥98%
  • T1677

    Tetracycline

    Polyketide; protein translation inhibitor, mamm...

    ≥90%
  • T5871

    Torin 2

    Tricyclic benzonaphthyridinone; mTORC1/2 inhibi...

    ≥98%
  • L960002

    LY-294002 Hydrochloride

    Inhibitor of PI3K.

    ≥98%
  • C1632

    Cefotaxime Acid

    β-lactam cephalosporin; penicillin binding pro...

    ≥91%
  • L9609

    Lycopene

    Carotene pigment found in red and green fruits ...

    ≥90%
  • C3251

    Cinnarizine

    FIASMA, L-type Ca2+ channel blocker, D2 antagon...

    ≥98%
  • P3456

    Pimobendan

    PDE3 inhibitor.

    ≥99%
  • A5283

    [Sar1]-Angiotensin II

    Peptide, derivative of AT II, involved in vasoc...

    ≥95%
  • M3368

    Mirtazapine

    Piperazine; 5-HT1 agonist, 5-HT2/3 and α2-adre...

    ≥98%
  • D1769

    Dermorphin

    Opioid peptide; μOR agonist.

    ≥96%